The current literature suggest that neoadjuvant therapy with EGFR-TKIs significantly reduce tumor volume, improve imaging response, and increase radical surgical resection rate, but does not translate into disease downstaging or pathological remission. The gene discussed is EGFR; the disease is neoplasm.